112 related articles for article (PubMed ID: 27734427)
21. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
22. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
23. A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cancer.
Di Franco CA; Jallous H; Porru D; Giliberto GL; Cebrelli T; Tinelli C; Rovereto B
Arch Ital Urol Androl; 2017 Mar; 89(1):55-59. PubMed ID: 28403597
[TBL] [Abstract][Full Text] [Related]
24. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
25. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
26. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
27. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
28. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
29. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of free/total PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from prostatic cancer].
Mosquera Madera J; Pinto Sierra I; Enguix Armada A; Sahagún Argüello JL
Actas Urol Esp; 2001 Oct; 25(9):651-5. PubMed ID: 11765549
[TBL] [Abstract][Full Text] [Related]
31. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
32. [Usefulness of PSA and its fractions in the diagnosis of prostate cancer].
Filella X; Truan D; Alcover J; Molina R; Luque P; Coca F; Ballesta AM
Med Clin (Barc); 2004 Feb; 122(7):241-4. PubMed ID: 15012870
[TBL] [Abstract][Full Text] [Related]
33. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
34. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
35. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
[TBL] [Abstract][Full Text] [Related]
36. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
37. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
39. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
40. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]